NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,417−0.18%BTC$81,133−0.12%VIX14.81−4.08%live tape · as of 23:00 UTC · 20 Sep
The Screen · Healthcare · Medical Devices
Edwards Lifesciences
EW · a US exchange · USD · Market cap $50.0B · 16,000 employees
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Positioning political selling, disclosed 2026-08-03
Options no verdict drawn today, left as found
Ethical passes the values gate
Price86.72 USD
Fair value87.90
Ethical score83.9/100
RatingOVERVALUED
Our investment reviews on this name
2026-08-28Read Accumulation89.83-3.5% to today
2026-07-02Read Markup85.96+0.9% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Edwards Lifesciences holds its Distribution at $86.72. Consolidating, no directional conviction, held for 486 days.
As held on the ledger · 2026-09-08
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 486 days
Price at the screen
$86.72
Valuation
51.62 trailing · 25.68 forward price to earnings
Values screen
PASS· score 83.9
Beta
0.85
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.15%
Below 33%
Interest-bearing debt is just 5.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.78%
Below 33%
Cash held in interest-bearing accounts and securities is 1.8% of assets, under the one-third limit.
Pass
Receivables
26.27%
Below 49%
Money owed to the company is 26.3% of assets, under the 49% limit.
Pass
Revenue purity
2.78%
Below 5%
Only 2.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades at roughly a 1% discount to our $87.90 fair value, moderate competitive moat, 13.60% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 1.4% margin of safety to the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +17% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Heart valves swapped through a thin tube
When surgeons replace a failing aortic valve they now thread a new one through a small incision rather than opening the chest. Edwards supplies the kit that makes this possible and that keeps demand steady across ageing populations.
Revenue is rising 17 percent, margins hold at 17 percent and the ethical screen is clear, yet the shares sit only two percent below our fair value at a forward multiple of 25.5 times. A moderate moat exists but the narrow gap to fair value leaves little reward for the price paid today.
Return on equity of just 10 percent signals limited pricing power once competition arrives or hospital budgets tighten. Any miss on procedure growth would quickly expose the valuation. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EW trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (27 analysts) rates it buy, with a mean price target of $97.
2026-07-28Markup$83.04-3.4%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (27 analysts) rates it buy, with a mean price target of $97.
2026-07-18Markup$85.96+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (27 analysts) rates it buy, with a mean price target of $97.
2026-07-03Markup$85.96+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$85.96Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
